Effect of serotonin transporter genotype on self-reported efficacy and activity changes of brain prefrontal area in response to placebo

M. Isawa, R. Tashiro, C. Naruse, Y. Yamaguchi, H. Itoh, Tomohiro Nishimura, Masatoshi Tomi, H. Shimada, H. Saito, M. Mochizuki, E. Nakashima

Research output: Contribution to journalArticle

Abstract

Patients benefit from drug therapy not only through pharmacological mechanisms, but also through non-pharmacological action (placebo effect), which may be mediated in part by the prefrontal area of the brain. We consider that the difference between responders and non-responders to placebo might be related to polymorphisms in the serotonin transporter-linked polymorphic region (5-HTTLPR). To study this idea, we performed a randomized double-blind clinical trial using caffeine and lactose (placebo). Activity in the prefrontal area of the brain was measured in terms of blood flow by means of near-infrared spectroscopy (NIRS) as an objective indicator. Self-reported feelings of drowsiness on established scales were used as subjective indicators. Twenty-one subjects in block A took caffeine on the first day and placebo on the third day, and 21 in block B took placebo on the first day and placebo on the third day. After placebo administration, improvement of sleepiness was significantly enhanced, a similar extent to that after caffeine medication. Among the 42 subjects, 22 showed S/S type polymorphism in the serotonin transporter (52.4 %), 17 showed S/L type (40.5 %) and 3 showed L/L type (7.10 %). Statistical analysis of the results indicate that subjects with L/L genotype showed a significantly greater placebo response in terms of both self-reported feeling of drowsiness and blood flow in the prefrontal area of the brain associated with working memory (46 area). Our results indicate that the L/L genotype of 5-HTTLPR, which is rare in Japanese (3.2 %) but common in Americans (32.2 %), may be associated with a greater placebo effect.

Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalPharmazie
Volume73
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Genotype
Placebos
Brain
Caffeine
Placebo Effect
Sleep Stages
Emotions
Near-Infrared Spectroscopy
Lactose
Short-Term Memory
Clinical Trials
Pharmacology
Drug Therapy

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Effect of serotonin transporter genotype on self-reported efficacy and activity changes of brain prefrontal area in response to placebo. / Isawa, M.; Tashiro, R.; Naruse, C.; Yamaguchi, Y.; Itoh, H.; Nishimura, Tomohiro; Tomi, Masatoshi; Shimada, H.; Saito, H.; Mochizuki, M.; Nakashima, E.

In: Pharmazie, Vol. 73, No. 1, 01.01.2018, p. 35-41.

Research output: Contribution to journalArticle

Isawa, M, Tashiro, R, Naruse, C, Yamaguchi, Y, Itoh, H, Nishimura, T, Tomi, M, Shimada, H, Saito, H, Mochizuki, M & Nakashima, E 2018, 'Effect of serotonin transporter genotype on self-reported efficacy and activity changes of brain prefrontal area in response to placebo', Pharmazie, vol. 73, no. 1, pp. 35-41. https://doi.org/10.1691/ph.2018.7740
Isawa, M. ; Tashiro, R. ; Naruse, C. ; Yamaguchi, Y. ; Itoh, H. ; Nishimura, Tomohiro ; Tomi, Masatoshi ; Shimada, H. ; Saito, H. ; Mochizuki, M. ; Nakashima, E. / Effect of serotonin transporter genotype on self-reported efficacy and activity changes of brain prefrontal area in response to placebo. In: Pharmazie. 2018 ; Vol. 73, No. 1. pp. 35-41.
@article{374bf4a815ae4f14b5884944a83e01fd,
title = "Effect of serotonin transporter genotype on self-reported efficacy and activity changes of brain prefrontal area in response to placebo",
abstract = "Patients benefit from drug therapy not only through pharmacological mechanisms, but also through non-pharmacological action (placebo effect), which may be mediated in part by the prefrontal area of the brain. We consider that the difference between responders and non-responders to placebo might be related to polymorphisms in the serotonin transporter-linked polymorphic region (5-HTTLPR). To study this idea, we performed a randomized double-blind clinical trial using caffeine and lactose (placebo). Activity in the prefrontal area of the brain was measured in terms of blood flow by means of near-infrared spectroscopy (NIRS) as an objective indicator. Self-reported feelings of drowsiness on established scales were used as subjective indicators. Twenty-one subjects in block A took caffeine on the first day and placebo on the third day, and 21 in block B took placebo on the first day and placebo on the third day. After placebo administration, improvement of sleepiness was significantly enhanced, a similar extent to that after caffeine medication. Among the 42 subjects, 22 showed S/S type polymorphism in the serotonin transporter (52.4 {\%}), 17 showed S/L type (40.5 {\%}) and 3 showed L/L type (7.10 {\%}). Statistical analysis of the results indicate that subjects with L/L genotype showed a significantly greater placebo response in terms of both self-reported feeling of drowsiness and blood flow in the prefrontal area of the brain associated with working memory (46 area). Our results indicate that the L/L genotype of 5-HTTLPR, which is rare in Japanese (3.2 {\%}) but common in Americans (32.2 {\%}), may be associated with a greater placebo effect.",
author = "M. Isawa and R. Tashiro and C. Naruse and Y. Yamaguchi and H. Itoh and Tomohiro Nishimura and Masatoshi Tomi and H. Shimada and H. Saito and M. Mochizuki and E. Nakashima",
year = "2018",
month = "1",
day = "1",
doi = "10.1691/ph.2018.7740",
language = "English",
volume = "73",
pages = "35--41",
journal = "Die Pharmazie",
issn = "0031-7144",
publisher = "Govi-Verlag Pharmazeutischer Verlag GmbH",
number = "1",

}

TY - JOUR

T1 - Effect of serotonin transporter genotype on self-reported efficacy and activity changes of brain prefrontal area in response to placebo

AU - Isawa, M.

AU - Tashiro, R.

AU - Naruse, C.

AU - Yamaguchi, Y.

AU - Itoh, H.

AU - Nishimura, Tomohiro

AU - Tomi, Masatoshi

AU - Shimada, H.

AU - Saito, H.

AU - Mochizuki, M.

AU - Nakashima, E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Patients benefit from drug therapy not only through pharmacological mechanisms, but also through non-pharmacological action (placebo effect), which may be mediated in part by the prefrontal area of the brain. We consider that the difference between responders and non-responders to placebo might be related to polymorphisms in the serotonin transporter-linked polymorphic region (5-HTTLPR). To study this idea, we performed a randomized double-blind clinical trial using caffeine and lactose (placebo). Activity in the prefrontal area of the brain was measured in terms of blood flow by means of near-infrared spectroscopy (NIRS) as an objective indicator. Self-reported feelings of drowsiness on established scales were used as subjective indicators. Twenty-one subjects in block A took caffeine on the first day and placebo on the third day, and 21 in block B took placebo on the first day and placebo on the third day. After placebo administration, improvement of sleepiness was significantly enhanced, a similar extent to that after caffeine medication. Among the 42 subjects, 22 showed S/S type polymorphism in the serotonin transporter (52.4 %), 17 showed S/L type (40.5 %) and 3 showed L/L type (7.10 %). Statistical analysis of the results indicate that subjects with L/L genotype showed a significantly greater placebo response in terms of both self-reported feeling of drowsiness and blood flow in the prefrontal area of the brain associated with working memory (46 area). Our results indicate that the L/L genotype of 5-HTTLPR, which is rare in Japanese (3.2 %) but common in Americans (32.2 %), may be associated with a greater placebo effect.

AB - Patients benefit from drug therapy not only through pharmacological mechanisms, but also through non-pharmacological action (placebo effect), which may be mediated in part by the prefrontal area of the brain. We consider that the difference between responders and non-responders to placebo might be related to polymorphisms in the serotonin transporter-linked polymorphic region (5-HTTLPR). To study this idea, we performed a randomized double-blind clinical trial using caffeine and lactose (placebo). Activity in the prefrontal area of the brain was measured in terms of blood flow by means of near-infrared spectroscopy (NIRS) as an objective indicator. Self-reported feelings of drowsiness on established scales were used as subjective indicators. Twenty-one subjects in block A took caffeine on the first day and placebo on the third day, and 21 in block B took placebo on the first day and placebo on the third day. After placebo administration, improvement of sleepiness was significantly enhanced, a similar extent to that after caffeine medication. Among the 42 subjects, 22 showed S/S type polymorphism in the serotonin transporter (52.4 %), 17 showed S/L type (40.5 %) and 3 showed L/L type (7.10 %). Statistical analysis of the results indicate that subjects with L/L genotype showed a significantly greater placebo response in terms of both self-reported feeling of drowsiness and blood flow in the prefrontal area of the brain associated with working memory (46 area). Our results indicate that the L/L genotype of 5-HTTLPR, which is rare in Japanese (3.2 %) but common in Americans (32.2 %), may be associated with a greater placebo effect.

UR - http://www.scopus.com/inward/record.url?scp=85040202109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040202109&partnerID=8YFLogxK

U2 - 10.1691/ph.2018.7740

DO - 10.1691/ph.2018.7740

M3 - Article

C2 - 29441949

AN - SCOPUS:85040202109

VL - 73

SP - 35

EP - 41

JO - Die Pharmazie

JF - Die Pharmazie

SN - 0031-7144

IS - 1

ER -